Find disease awareness content and relevant supporting materials

Pulmonary hypertension is a multifactorial disease with a high morbidity and mortality.

Bayer HealthCare has submitted the oral investigational drug riociguat to treat patients with inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the Phase III A DUE study (NCT03904693), which showed an investigational once-daily, single tablet combination therapy, also known as fixed dose combination, of macitentan 10 mg and tadalafil 40 mg (M/T STCT), significantly improved pulmonary hemodynamics (blood flow through pulmonary blood vessels) versus macitentan and tadalafil monotherapies in pulmonary arterial hypertension (PAH) patients with World Health Organization (WHO) functional class (FC) II or III.[1] The data were presented as a Late-Breaking Clinical Trial presentation during the American College of Cardiology’s 72nd Annual Scientific Session & Expo Together With World Heart Federation’s World Congress of Cardiology.

Despite using vasoactive and PH specific therapies, the in-hospital mortality of severe pulmonary hypertension (PH) with right heart failure (RHF) is high.

End-stage heart failure (HF) frequently needs continuous inotropic support in hospital and has high morbidity and mortality in absence of heart transplantation.

The FDA has on 8 October 2013 approved Adempas (riociguat) from Bayer HealthCare to treat adults with two forms of...

The aim of the study is to assess safety, tolerability and clinical effects of different doses of riociguat in patients...

Pulmonary arterial hypertension is a disease characterised by pathological changes in the pulmonary arteries leading to a progressive increase in...

The clinical course of heart failure is characterised by progressive worsening of cardiac function and symptoms. Patients progress to a condition where traditional treatment is no longer effective and advanced therapies...

Background: Differentiating heart failure from chronic obstructive pulmonary disease (COPD) in a patient presenting with breathlessness is difficult but may have implications for outcome.